{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:45:36Z","timestamp":1761630336354,"version":"build-2065373602"},"reference-count":358,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1016\/j.jaad.2003.12.003","type":"journal-article","created":{"date-parts":[[2004,3,20]],"date-time":"2004-03-20T11:12:07Z","timestamp":1079781127000},"page":"495-528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Vaccines and immunotherapies for the prevention of infectious diseases having cutaneous manifestations"],"prefix":"10.1016","volume":"50","author":[{"given":"Jashin J","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie R","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen K","family":"Tyring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2003.12.003_BIB1","first-page":"241","article-title":"Ten great public health achievements","volume":"48","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB2","first-page":"243","article-title":"Achievements in public health, 1900-1999","volume":"48","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 3","key":"10.1016\/j.jaad.2003.12.003_BIB3","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/S0264-410X(99)00306-0","article-title":"Demographic impact of vaccination","volume":"17","author":"Bonanni","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2003.12.003_BIB4","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJM199112193252504","article-title":"Strategies for the global eradication of poliomyelitis by the year 2000","volume":"325","author":"Wright","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB5","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.288.20.2532","article-title":"State of the world's vaccines and immunizations","volume":"288","author":"Brundtland","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB6","first-page":"1","article-title":"Measles update","volume":"3","year":"2003","journal-title":"National Immunization Program"},{"issue":"Suppl 3","key":"10.1016\/j.jaad.2003.12.003_BIB7","first-page":"S205","article-title":"HIV vaccine development and evaluation","volume":"14","author":"Heyward","year":"1998","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.jaad.2003.12.003_BIB8","series-title":"Vaccines","first-page":"74","article-title":"Smallpox and vaccinia","author":"Henderson","year":"1999"},{"key":"10.1016\/j.jaad.2003.12.003_BIB9","doi-asserted-by":"crossref","unstructured":"Is smallpox history? Lancet 1999;353:1539","DOI":"10.1016\/S0140-6736(99)00080-X"},{"key":"10.1016\/j.jaad.2003.12.003_BIB10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3201\/eid0504.990429","article-title":"Current status of smallpox vaccine","volume":"5","author":"LeDuc","year":"1999","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB11","first-page":"215","article-title":"The destruction of smallpox virus stocks in national repositories","volume":"3","author":"Roizman","year":"1994","journal-title":"Infect Agents Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB12","first-page":"11","article-title":"The remaining smallpox virus stocks are too valuable to be destroyed","volume":"10","author":"Joklik","year":"1996","journal-title":"Scientist"},{"key":"10.1016\/j.jaad.2003.12.003_BIB13","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM199808203390811","article-title":"Poxvirus dilemmas","volume":"339","author":"Breman","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB14","unstructured":"Smallpox eradication: destruction of variola virus stocks. Paper presented at: World Health Assembly, May 24, 1999"},{"year":"1988","series-title":"Smallpox and its eradication","author":"Fenner","key":"10.1016\/j.jaad.2003.12.003_BIB15"},{"key":"10.1016\/j.jaad.2003.12.003_BIB16","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-138-6-200303180-00014","article-title":"Evaluation of 21st-century risks of smallpox vaccination and policy options","volume":"138","author":"Lane","year":"2003","journal-title":"Ann Intern Med"},{"year":"2002","series-title":"Smallpox response plan and guidelines (version 3.0). Atlanta (GA): US","key":"10.1016\/j.jaad.2003.12.003_BIB17"},{"key":"10.1016\/j.jaad.2003.12.003_BIB18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/rmv.382","article-title":"The new cell culture smallpox vaccine should be offered to the general population","volume":"13","author":"Bicknell","year":"2003","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.7883\/yoken.JJID.2002.112","article-title":"Duration of immunity after smallpox vaccination","volume":"55","author":"Arita","year":"2002","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB20","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1056\/NEJMra020025","article-title":"Diagnosis and management of smallpox","volume":"346","author":"Breman","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB21","first-page":"492","article-title":"Update","volume":"52","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB22","first-page":"1","article-title":"Smallpox vaccination and adverse reactions. Guidance for clinicians","volume":"52","author":"Cono","year":"2003","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB23","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1001\/archderm.1997.03890440061010","article-title":"Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus\u2013infected patients treated with cidofovir","volume":"133","author":"Meadows","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0891-5520(20)30323-8","article-title":"Measles, mumps, and rubella vaccines","volume":"4","author":"Wharton","year":"1990","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jaad.2003.12.003_BIB25","first-page":"1","article-title":"Measles, mumps, and rubella","volume":"47","year":"1998","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jama.1985.03360020085030","article-title":"Some issues relating to rubella vaccine","volume":"254","author":"Preblud","year":"1985","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB27","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1056\/NEJM199505113321904","article-title":"Safe administration of the measles vaccine to children allergic to eggs","volume":"332","author":"James","year":"1995","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2003.12.003_BIB28","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/infdis\/170.Supplement_1.S1","article-title":"Putting a stop to a serial killer","volume":"170","author":"Gellin","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0140-6736(52)91357-3","article-title":"Infectiousness of communicable diseases in the household (measles, chicken pox, and mumps)","volume":"2","author":"Hope-Simpson","year":"1952","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2003.12.003_BIB30","first-page":"1","article-title":"Measles eradication","volume":"46","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB31","first-page":"557","article-title":"Measles","volume":"49","year":"2000","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB32","first-page":"120","article-title":"Measles","volume":"51","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB33","first-page":"i","article-title":"Measles","volume":"50","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB34","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0140-6736(96)07493-4","article-title":"Mortality by cause for eight regions of the world","volume":"349","author":"Murray","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2003.12.003_BIB35","first-page":"567","article-title":"Measles-specific lymphocyte reactivity and serum antibody in subjects with different measles histories","volume":"134","author":"Krause","year":"1980","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.jaad.2003.12.003_BIB36","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1542\/peds.97.5.613","article-title":"An evaluation of measles revaccination among school-entry-aged children","volume":"97","author":"Watson","year":"1996","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2003.12.003_BIB37","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1093\/oxfordjournals.aje.a114675","article-title":"A persistent outbreak of measles despite appropriate control measures","volume":"126","author":"Davis","year":"1987","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/clinids\/5.3.477","article-title":"Further-attenuated measles vaccine","volume":"5","author":"Krugman","year":"1983","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB39","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2105\/AJPH.79.4.475","article-title":"The role of secondary vaccine failures in measles outbreaks","volume":"79","author":"Mathias","year":"1989","journal-title":"Am J Public Health"},{"key":"10.1016\/j.jaad.2003.12.003_BIB40","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/00006454-198709000-00012","article-title":"Measles vaccine failure after documented seroconversion","volume":"6","author":"Reyes","year":"1987","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jaad.2003.12.003_BIB41","first-page":"939","article-title":"Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins","volume":"1","author":"Pelota","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2003.12.003_BIB42","first-page":"601","article-title":"Measles","volume":"38","year":"1989","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB43","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1542\/peds.59.4.505","article-title":"Epidemiologic studies of measles, measles vaccine, and subacute sclerosing panencephalitis","volume":"59","author":"Modlin","year":"1977","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2003.12.003_BIB44","first-page":"585","article-title":"Subacute sclerosing panencephalitis surveillance","volume":"31","year":"1982","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB45","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0733-8619(18)31062-4","article-title":"Subacute sclerosing panencephalitis, current status","volume":"3","author":"Dyken","year":"1985","journal-title":"Neurol Clin"},{"key":"10.1016\/j.jaad.2003.12.003_BIB46","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM196802012780501","article-title":"Live, attenuated mumps vaccine","volume":"278","author":"Hilleman","year":"1968","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB47","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM196702022760501","article-title":"Live attenuated mumps","volume":"276","author":"Weibel","year":"1967","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB48","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0022-3476(68)80334-8","article-title":"Field evaluation of live virus mumps vaccine","volume":"72","author":"Sugg","year":"1968","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaad.2003.12.003_BIB49","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1001\/jama.1987.03390180073026","article-title":"The effect of a school entry law on mumps activity in a school district","volume":"257","author":"Chaiken","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB50","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/oxfordjournals.aje.a114037","article-title":"Clinical mumps vaccine efficacy","volume":"121","author":"Kim-Farley","year":"1985","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB51","first-page":"909","article-title":"Effectiveness of mumps vaccine in a school outbreak","volume":"139","author":"Sullivan","year":"1985","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.jaad.2003.12.003_BIB52","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/infdis\/158.6.1253","article-title":"A large outbreak of mumps in the post vaccine era","volume":"158","author":"Wharton","year":"1988","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB53","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-3476(05)80726-7","article-title":"Mumps outbreak in a highly vaccinated population","volume":"119","author":"Hersh","year":"1991","journal-title":"J Pediatr"},{"issue":"S-3","key":"10.1016\/j.jaad.2003.12.003_BIB54","first-page":"1","article-title":"Mumps surveillance","volume":"44","year":"1995","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB55","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1542\/peds.61.1.5","article-title":"Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines","volume":"61","author":"Weibel","year":"1978","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2003.12.003_BIB56","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM197007302830507","article-title":"Clinical and serologic studies of an outbreak of rubella in a vaccinated population","volume":"283","author":"Chang","year":"1970","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB57","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0031-3955(16)36909-7","article-title":"Rubella and mumps vaccines","volume":"37","author":"Bakshi","year":"1990","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.jaad.2003.12.003_BIB58","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/jama.1973.03220330013003","article-title":"Immunologic properties of RA 27-3 rubella virus vaccine. A comparison with strains presently licensed in the United States","volume":"225","author":"Plotkin","year":"1973","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB59","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00000441-198003000-00002","article-title":"Live attenuated rubella virus vaccine","volume":"279","author":"Gershon","year":"1980","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jaad.2003.12.003_BIB60","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJM196702022760502","article-title":"Live attenuated mumps-virus vaccine","volume":"276","author":"Hilleman","year":"1967","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB61","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1001\/jama.1988.03720210023022","article-title":"Rubella antibody persistence after immunization","volume":"259","author":"Chu","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB62","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.285.6337.253","article-title":"Rubella vaccination","volume":"285","author":"O'Shea","year":"1982","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.jaad.2003.12.003_BIB63","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3928\/0090-4481-19970601-06","article-title":"Rubella immunization","volume":"26","author":"Kimberlin","year":"1997","journal-title":"Pediatr Ann"},{"key":"10.1016\/j.jaad.2003.12.003_BIB64","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1017\/S0022172400021720","article-title":"Vaccination of adults with Wistar RA 27\/3 rubella vaccine","volume":"69","author":"Freestone","year":"1971","journal-title":"J Hyg (Lond)"},{"key":"10.1016\/j.jaad.2003.12.003_BIB65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/oxfordjournals.aje.a113276","article-title":"A controlled comparison of joint reactions among women receiving one of two rubella vaccines","volume":"115","author":"Polk","year":"1982","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB66","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/oxfordjournals.epirev.a036221","article-title":"Rubella vaccination in the United States","volume":"2","author":"Preblud","year":"1980","journal-title":"Epidemiol Rev"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2003.12.003_BIB67","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1093\/infdis\/171.Supplement_1.S70","article-title":"Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children","volume":"171","author":"Balcarek","year":"1995","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2003.12.003_BIB68","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1093\/infdis\/171.Supplement_1.S44","article-title":"Clinical experience with an inactivated hepatitis A vaccine","volume":"171","author":"Clemens","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB69","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00006454-199305000-00001","article-title":"Safety and immunogenicity of hepatitis A vaccine in healthy children","volume":"12","author":"Horng","year":"1993","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jaad.2003.12.003_BIB70","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/infdis\/169.5.996","article-title":"Safety and immunogenicity of an inactivated hepatitis A vaccine","volume":"169","author":"Westblom","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB71","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/00006454-199312000-00002","article-title":"Safety, tolerability and immunogenicity of a formalin-inactivated hepatitis A vaccine (VAQTA) in rural Kentucky children","volume":"12","author":"Block","year":"1993","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jaad.2003.12.003_BIB72","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199208133270702","article-title":"A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children","volume":"327","author":"Werzberger","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB73","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1001\/jama.1994.03510410040030","article-title":"Protection against hepatitis A by an inactivated vaccine","volume":"271","author":"Innis","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB74","first-page":"1","article-title":"Prevention of hepatitis A through active or passive immunization","volume":"45","year":"1996","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB75","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/(SICI)1096-9071(199607)49:3<235::AID-JMV13>3.0.CO;2-B","article-title":"Duration of protection from clinical hepatitis A disease after vaccination with VAQTA","volume":"49","author":"Wiens","year":"1996","journal-title":"J Med Virol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB76","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/jmv.1890440425","article-title":"Inactivated hepatitis A vaccine","volume":"44","author":"Damme","year":"1994","journal-title":"J Med Virol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB77","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0264-410X(96)00242-3","article-title":"Inactivated hepatitis A vaccine","volume":"15","author":"Wiedermann","year":"1997","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"10.1016\/j.jaad.2003.12.003_BIB78","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0168-8278(05)80379-4","article-title":"Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations","volume":"18","author":"Nalin","year":"1993","journal-title":"J Hepatol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB79","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1542\/peds.108.5.1123","article-title":"Childhood hepatitis B virus infections in the United States before hepatitis B immunization","volume":"108","author":"Armstrong","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2003.12.003_BIB80","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/jama.1996.03540220020011","article-title":"The heritage of hepatitis B vaccine","volume":"276","author":"Douglas","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB81","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/0003-4819-97-3-362","article-title":"The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control multicenter efficacy trial among homosexual men","volume":"97","author":"Francis","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB82","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1056\/NEJM198010093031501","article-title":"Hepatitis B vaccine","volume":"303","author":"Szmuness","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB83","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0889-8553(21)00253-3","article-title":"Hepatitis vaccines","volume":"24","author":"Katkov","year":"1995","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.jaad.2003.12.003_BIB84","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/infdis\/149.6.1019","article-title":"Hepatitis B vaccination in the elderly","volume":"149","author":"Denis","year":"1984","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB85","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/oxfordjournals.aje.a114061","article-title":"The control of hepatitis B virus infection with vaccine in Yupik Eskimos. Demonstration of safety, immunogenicity, and efficacy under field conditions","volume":"121","author":"Heyward","year":"1985","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB86","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1001\/jama.1993.03510240043029","article-title":"Hepatitis B vaccine responsiveness in Connecticut public safety personnel","volume":"270","author":"Roome","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB87","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1001\/jama.1993.03510240047030","article-title":"Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers","volume":"270","author":"Wood","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB88","first-page":"295","article-title":"Hepatitis B virus infection, hepatitis B vaccine, and hepatitis B immune globulin","volume":"45","author":"Zimmerman","year":"1997","journal-title":"J Fam Pract"},{"key":"10.1016\/j.jaad.2003.12.003_BIB89","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S0264-410X(97)00254-5","article-title":"Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system","volume":"16","author":"Thoelen","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2003.12.003_BIB90","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0264-410X(99)00088-2","article-title":"A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant","volume":"17","author":"Heineman","year":"1999","journal-title":"Vaccine"},{"issue":"suppl","key":"10.1016\/j.jaad.2003.12.003_BIB91","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S0264-410X(98)00300-4","article-title":"Novel hepatitis B vaccines","volume":"16","author":"Jilg","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2003.12.003_BIB92","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2893.1996.tb00079.x","article-title":"Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens","volume":"3","author":"Hourvitz","year":"1996","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jaad.2003.12.003_BIB93","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0264-410X(92)90391-V","article-title":"Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein","volume":"10","author":"Yap","year":"1992","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2003.12.003_BIB94","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/infdis\/175.3.678","article-title":"A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, Pre-S1, and Pre-S2 particles for revaccination of healthy adult nonresponders","volume":"175","author":"Bertino","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB95","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0168-8278(88)80032-1","article-title":"Persistence of specific antibodies after hepatitis B vaccination","volume":"6","author":"Jilg","year":"1988","journal-title":"J Hepatol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB96","unstructured":"Stevens CE, Taylor FE, Tong MJ, et al. Hepatitis B vaccine: an overview. In: Vyas GN, Dienstag JL, Hoofnagle JH, editors. Viral hepatitis and liver disease. Orlando: Grune & Stratton; 1984. p. 275-91"},{"key":"10.1016\/j.jaad.2003.12.003_BIB97","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJM198607243150401","article-title":"Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men","volume":"315","author":"Hadler","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB98","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1542\/peds.90.1.170","article-title":"Prospects for control of hepatitis B virus infection","volume":"90","author":"Stevens","year":"1992","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2003.12.003_BIB99","first-page":"780","article-title":"Notice to readers","volume":"48","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 2","key":"10.1016\/j.jaad.2003.12.003_BIB100","first-page":"169","article-title":"Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine","volume":"63","author":"Andre","year":"1987","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jaad.2003.12.003_BIB101","first-page":"1","article-title":"Update","volume":"45","year":"1996","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"suppl","key":"10.1016\/j.jaad.2003.12.003_BIB102","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0264-410X(90)90222-8","article-title":"Overview of 5-year clinical experience with a yeast-derived hepatitis B vaccine","volume":"8","author":"Andre","year":"1990","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2003.12.003_BIB103","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/003655498750003465","article-title":"Immune thrombocytopenic purpura after recombinant hepatitis B vaccine","volume":"30","author":"Neau","year":"1998","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB104","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/adc.78.3.273","article-title":"Thrombocytopenic purpura as adverse reaction to recombinant hepatitis B vaccine","volume":"78","author":"Ronchi","year":"1998","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaad.2003.12.003_BIB105","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(94)90777-3","article-title":"Thrombocytopenic purpura after recombinant hepatitis B vaccine","volume":"334","author":"Poullin","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2003.12.003_BIB106","first-page":"191","article-title":"Suspected hepatitis B vaccination related vasculitis","volume":"26","author":"Hello","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB107","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1136\/thx.48.5.580","article-title":"Pulmonary and cutaneous vasculitis following hepatitis B vaccination","volume":"48","author":"Allen","year":"1993","journal-title":"Thorax"},{"key":"10.1016\/j.jaad.2003.12.003_BIB108","first-page":"1687","article-title":"The development of rheumatoid arthritis after recombinant hepatitis B vaccination","volume":"25","author":"Pope","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000018054","article-title":"Lichen planus as a side effect of HBV vaccination","volume":"198","author":"Rebora","year":"1999","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2003.12.003_BIB110","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1440-0960.1997.tb01134.x","article-title":"Lichenoid reaction to hepatitis B vaccination","volume":"38","author":"Saywell","year":"1997","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB111","series-title":"Viral hepatitis and liver disease","first-page":"716","article-title":"Control of hepatitis B in Asia","author":"Chen","year":"1991"},{"key":"10.1016\/j.jaad.2003.12.003_BIB112","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/00006454-200110000-00011","article-title":"Safety immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants","volume":"20","author":"Yeh","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jaad.2003.12.003_BIB113","first-page":"S13","article-title":"Clinical evaluation of a DTaP-HepB-IPV combined vaccine","volume":"9","author":"Partridge","year":"2003","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jaad.2003.12.003_BIB114","unstructured":"Pediarix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivates Poliovirus Vaccine Combined] prescribing information. Rixensart [Belgium]: SmithKline Beecham Biologicals; 2002"},{"key":"10.1016\/j.jaad.2003.12.003_BIB115","first-page":"203","article-title":"FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined (Pediarix) for use in infants","volume":"52","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB116","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1542\/peds.109.4.e58","article-title":"Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants","volume":"109","author":"Zepp","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2003.12.003_BIB117","first-page":"379","article-title":"FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined (Pediarix) for use in infants","volume":"52","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB118","first-page":"1","article-title":"Prevention of varicella","volume":"48","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB119","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJM200103293441310","article-title":"Varicella vaccine","volume":"344","author":"Arvin","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB120","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1056\/NEJM200103293441302","article-title":"The effectiveness of the varicella vaccine in clinical practice","volume":"344","author":"Vazquez","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB121","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.284.10.1271","article-title":"Postlicensure safety surveillance for varicella vaccine","volume":"284","author":"Wise","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB122","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/clinids\/24.5.753","article-title":"Varicella-zoster virus vaccine","volume":"24","author":"White","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB123","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1542\/peds.78.4.736","article-title":"Clinical overview of varicella vaccine","volume":"78","author":"Takahashi","year":"1986","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2003.12.003_BIB124","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1542\/peds.94.4.524","article-title":"Experience and reason","volume":"94","author":"Asano","year":"1994","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2003.12.003_BIB125","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJM198405313102201","article-title":"Live attenuated varicella virus vaccine. Efficacy trial in healthy children","volume":"310","author":"Weibel","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB126","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/0264-410X(91)90189-D","article-title":"Oka\/Merck varicella vaccine in healthy children","volume":"9","author":"Kuter","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2003.12.003_BIB127","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/infdis\/162.4.794","article-title":"Cell-mediated immune responses after immunization of healthy seronegative children with varicella vaccine","volume":"162","author":"Watson","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB128","first-page":"604","article-title":"Varicella vaccine (Varivax) in healthy children and adolescents","volume":"87","author":"White","year":"1991","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2003.12.003_BIB129","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/clinids\/20.2.316","article-title":"Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine","volume":"20","author":"Watson","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB130","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/infdis\/169.1.197","article-title":"Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine","volume":"169","author":"Watson","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB131","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1542\/peds.75.4.667","article-title":"Long-term protective immunity of recipients of the OKA strain of live varicella vaccine","volume":"75","author":"Asano","year":"1985","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2003.12.003_BIB132","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00006454-199201000-00006","article-title":"Modified cases of chickenpox after varicella vaccination","volume":"11","author":"White","year":"1992","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jaad.2003.12.003_BIB133","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1542\/peds.91.1.17","article-title":"Modified chickenpox in children immunized with the Oka\/Merck varicella vaccine","volume":"91","author":"Watson","year":"1993","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2003.12.003_BIB134","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1542\/peds.105.1.84","article-title":"Postexposure effectiveness of varicella vaccine","volume":"105","author":"Watson","year":"2000","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2003.12.003_BIB135","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/0264-410X(95)00046-4","article-title":"Safety, tolerability, and immunogenicity of two regimens of Oka\/Merck varicella vaccine (Varivax) in healthy adolescents and adults","volume":"13","author":"Kuter","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2003.12.003_BIB136","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1056\/NEJM199111283252204","article-title":"The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. The Varicella Vaccine Collaborative Study Group","volume":"325","author":"Hardy","year":"1991","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"10.1016\/j.jaad.2003.12.003_BIB137","first-page":"79","article-title":"Early results of a trial of the Oka-strain varicella vaccine in children with leukaemia or other malignancies in Sweden","volume":"61","author":"Heller","year":"1985","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jaad.2003.12.003_BIB138","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jama.1984.03350030023016","article-title":"Live attenuated varicella vaccine","volume":"252","author":"Gershon","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB139","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0022-3476(05)82872-0","article-title":"Live attenuated varicella vaccine","volume":"116","author":"Tsolia","year":"1990","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaad.2003.12.003_BIB140","doi-asserted-by":"crossref","unstructured":"Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, K KB, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002;347:26-34","DOI":"10.1056\/NEJMoa013441"},{"key":"10.1016\/j.jaad.2003.12.003_BIB141","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1212\/WNL.30.6.582","article-title":"Selective decline in cellular immune response to varicella-zoster in the elderly","volume":"30","author":"Miller","year":"1980","journal-title":"Neurology"},{"key":"10.1016\/j.jaad.2003.12.003_BIB142","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/archinte.1982.00340150091017","article-title":"Immune responses to varicella-zoster in the aged","volume":"142","author":"Burke","year":"1982","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB143","doi-asserted-by":"crossref","unstructured":"Hayward A, Levin M, Wolf W, Angelova G. Varicella-zoster virus-specific immunity after herpes zoster. J Infect Dis 1991;163:873-5","DOI":"10.1093\/infdis\/163.4.873"},{"key":"10.1016\/j.jaad.2003.12.003_BIB144","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/infdis\/170.3.522","article-title":"Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine","volume":"170","author":"Levin","year":"1994","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2003.12.003_BIB145","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1086\/514264","article-title":"Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older","volume":"178","author":"Levin","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB146","first-page":"151","article-title":"Use of varicella vaccines to prevent herpes zoster in older individuals","volume":"39","author":"Levin","year":"2001","journal-title":"Arch Virol Suppl"},{"key":"10.1016\/j.jaad.2003.12.003_BIB147","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/00006454-199510000-00011","article-title":"Over five-year follow-up of Oka\/Merck varicella vaccine recipients in 465 infants and adolescents","volume":"14","author":"Clements","year":"1995","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jaad.2003.12.003_BIB148","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1542\/peds.92.6.833","article-title":"Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka\/Merck varicella vaccine","volume":"92","author":"Bernstein","year":"1993","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2003.12.003_BIB149","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1542\/peds.76.4.512","article-title":"Epidemiology of herpes zoster in children and adolescents","volume":"76","author":"Guess","year":"1985","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2003.12.003_BIB150","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/infdis\/160.3.535","article-title":"Herpes zoster in an adult recipient of live attenuated varicella vaccine","volume":"160","author":"Hammerschlag","year":"1989","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB151","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/infdis\/155.4.633","article-title":"Molecular epidemiology of live, attenuated varicella virus vaccine in children and in normal adults","volume":"155","author":"Gelb","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB152","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0891-5520(05)70315-9","article-title":"Clinical trials of varicella vaccine in healthy children","volume":"10","author":"White","year":"1996","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jaad.2003.12.003_BIB153","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1172\/JCI0216204","article-title":"Development of an improved vaccine for anthrax","volume":"110","author":"Leppla","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2003.12.003_BIB154","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1128\/iai.49.2.291-297.1985","article-title":"Demonstration of a capsule plasmid in Bacillus anthracis","volume":"49","author":"Green","year":"1985","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2003.12.003_BIB155","first-page":"557","article-title":"Virulence and immunogenicity in experimental animals of Bacillus anthracis strains harbouring or lacking 110 MDa and 60 MDa plasmids","volume":"132","author":"Uchida","year":"1986","journal-title":"J Gen Microbiol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB156","series-title":"Comprehensive sourcebook of bacterial protein toxins","first-page":"243","article-title":"The bifactorial Bacillus anthracis lethal and oedema toxins","author":"Leppla","year":"1999"},{"key":"10.1016\/j.jaad.2003.12.003_BIB157","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1128\/jb.171.2.722-730.1989","article-title":"Molecular characterization and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracis","volume":"171","author":"Makino","year":"1989","journal-title":"J Bacteriol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB158","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1128\/am.11.4.330-334.1963","article-title":"Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures","volume":"11","author":"Puziss","year":"1963","journal-title":"Appl Microbiol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB159","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0264-410X(84)90003-3","article-title":"Anthrax","volume":"2","author":"Hambleton","year":"1984","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2003.12.003_BIB160","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2105\/AJPH.52.4.632","article-title":"Field evaluation of a human anthrax vaccine","volume":"52","author":"Brachman","year":"1962","journal-title":"Am J Public Health"},{"key":"10.1016\/j.jaad.2003.12.003_BIB161","unstructured":"FDA. Biological products: bacterial vaccines and toxoids; implementation of efficacy review. Proposed rule. Federal Register 50:1002-117"},{"year":"1959","series-title":"Report of the Committee of Inquiry on Anthrax","key":"10.1016\/j.jaad.2003.12.003_BIB162"},{"key":"10.1016\/j.jaad.2003.12.003_BIB163","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4049\/jimmunol.73.6.387","article-title":"Studies on immunity in anthrax. Immunizing activity of alum-precipitated protective antigen","volume":"73","author":"Wright","year":"1954","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB164","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1016\/S0264-410X(01)00021-4","article-title":"Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin","volume":"19","author":"Fellows","year":"2001","journal-title":"Vaccine"},{"year":"2000","series-title":"Biosafety in microbiological and biomedical laboratories","key":"10.1016\/j.jaad.2003.12.003_BIB165"},{"key":"10.1016\/j.jaad.2003.12.003_BIB166","unstructured":"Is it safe? Does it work? In: Joellenbeck LM, Zwanziger LL, Durch JS, Strom BL, editors. The anthrax vaccine. Washington, DC: National Academy Press; 2002. p. 265"},{"key":"10.1016\/j.jaad.2003.12.003_BIB167","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1128\/jb.85.1.230-236.1963","article-title":"Studies on immunity in anthrax. Gel-adsorbed protective antigen for immunization of man","volume":"85","author":"Puziss","year":"1963","journal-title":"J Bacteriol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB168","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0264-410X(00)00174-2","article-title":"Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans","volume":"19","author":"Pittman","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2003.12.003_BIB169","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1128\/iai.52.2.356-363.1986","article-title":"Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity","volume":"52","author":"Turnbull","year":"1986","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2003.12.003_BIB170","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0264-410X(98)80112-6","article-title":"Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques","volume":"16","author":"Ivins","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2003.12.003_BIB171","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1099\/00221287-147-6-1677","article-title":"The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores","volume":"147","author":"Welkos","year":"2001","journal-title":"Microbiology"},{"key":"10.1016\/j.jaad.2003.12.003_BIB172","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1128\/IAI.70.2.661-664.2002","article-title":"Anthrax spores make an essential contribution to vaccine efficacy","volume":"70","author":"Brossier","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2003.12.003_BIB173","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1128\/IAI.68.8.4549-4558.2000","article-title":"Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax","volume":"68","author":"Cohen","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2003.12.003_BIB174","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1006\/mpat.1993.1037","article-title":"Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice","volume":"14","author":"Welkos","year":"1993","journal-title":"Microb Pathog"},{"key":"10.1016\/j.jaad.2003.12.003_BIB175","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1128\/IAI.67.2.562-567.1999","article-title":"Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produced protective antigen","volume":"67","author":"Barnard","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2003.12.003_BIB176","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0966-842X(96)10048-2","article-title":"DNA immunization","volume":"4","author":"Hassett","year":"1996","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB177","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1365-2672.1999.00901.x","article-title":"Presentation of protective antigen to the mouse immune system","volume":"87","author":"Williamson","year":"1999","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB178","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0264-410X(98)00210-2","article-title":"Protection against anthrax by vaccination with a DNA plasmid encoding anthrax protective antigen","volume":"17","author":"Gu","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2003.12.003_BIB179","unstructured":"Development and testing of vaccines against anthrax. Request for proposal. Bethesda (MD): National Institute of Allergy and Infectious Diseases; 2002"},{"key":"10.1016\/j.jaad.2003.12.003_BIB180","first-page":"1","article-title":"Recommendations for the use of Lyme disease vaccine","volume":"48","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB181","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1084\/jem.183.1.261","article-title":"Direct demonstration of antigenic substitution of Borrelia burgdorferi ex vivo","volume":"183","author":"Montgomery","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB182","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1086\/515684","article-title":"Differential expression of Borrelia burgdorferi genes during erythema migrans and Lyme arthritis","volume":"178","author":"Fikrig","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB183","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1073\/pnas.92.7.2909","article-title":"Induction of an outer surface protein on Borrelia burgdorferi during tick feeding","volume":"92","author":"Schwan","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB184","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1084\/jem.183.1.271","article-title":"Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine","volume":"183","author":"da Silva","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB185","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1128\/IAI.67.1.30-35.1999","article-title":"Influence of outer surface protein A antibody on Borrelia burgdorferi within feeding ticks","volume":"67","author":"da Silva","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2003.12.003_BIB186","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/infdis\/175.2.400","article-title":"Immunization with outer surface protein (Osp) A, but not OspC, provides cross-protection of mice challenged with North American isolates of Borrelia burgdorferi","volume":"175","author":"Probert","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB187","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1128\/iai.60.3.773-777.1992","article-title":"Long-term protection of mice from Lyme disease by vaccination with OspA","volume":"60","author":"Fikrig","year":"1992","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2003.12.003_BIB188","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1126\/science.2237407","article-title":"Protection of mice against the Lyme disease agent by immunizing with recombinant OspA","volume":"250","author":"Fikrig","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.jaad.2003.12.003_BIB189","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0264-410X(97)00066-2","article-title":"Immunization with a polyvalent OspA vaccine protects mice against Ixodes ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii","volume":"15","author":"Gern","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2003.12.003_BIB190","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0264-410X(94)00027-K","article-title":"The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi","volume":"13","author":"Golde","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2003.12.003_BIB191","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/infdis\/171.5.1368","article-title":"Efficacy of human Lyme disease vaccine formulations in a mouse model","volume":"171","author":"Telford","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB192","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1073\/pnas.89.12.5418","article-title":"Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice","volume":"89","author":"Fikrig","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB193","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1128\/iai.63.9.3543-3549.1995","article-title":"Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi","volume":"63","author":"Chang","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2003.12.003_BIB194","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/S0264-410X(97)00133-3","article-title":"The outer surface protein A (OspA) vaccine against Lyme disease","volume":"15","author":"Van Hoecke","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2003.12.003_BIB195","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/S0264-410X(96)00146-6","article-title":"Evaluation of the safety, reactogenicity and immunologenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults","volume":"14","author":"Van Hoecke","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2003.12.003_BIB196","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1086\/514779","article-title":"Alternative vaccination schedules (0, 1, and 6 months versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine","volume":"28","author":"Hoecke","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB197","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJM199807233390401","article-title":"Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant","volume":"339","author":"Steere","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB198","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/infdis\/172.5.1324","article-title":"Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease","volume":"172","author":"Schoen","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB199","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJM199807233390402","article-title":"A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease","volume":"339","author":"Sigal","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB200","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/archinte.161.4.554","article-title":"The cost-effectiveness of vaccination against Lyme disease","volume":"161","author":"Shadick","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB201","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJM198901193200301","article-title":"Rapid emergence of a focal epidemic of Lyme disease in coastal Massachusetts","volume":"320","author":"Lastavica","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB202","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0891-5520(05)70274-9","article-title":"Lyme vaccine","volume":"15","author":"Rahn","year":"2001","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jaad.2003.12.003_BIB203","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1542\/peds.60.5.730","article-title":"Haemophilus influenzae type b capsular polysaccharide vaccine in children","volume":"60","author":"Peltola","year":"1977","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2003.12.003_BIB204","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/147.6.1100","article-title":"The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b","volume":"147","author":"K\u00e4yhty","year":"1983","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB205","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJM198709173171201","article-title":"Efficacy of Haemophilus influenzae type b polysaccharide diphtheria toxoid conjugate vaccine in infancy","volume":"317","author":"Eskola","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB206","doi-asserted-by":"crossref","unstructured":"Eskola J, Peltola H, K\u00e4yhty H, Takala AK, M\u00e4kel\u00e4 PH. Finnish efficacy trials with Haemophilus influenzae type b vaccines. J Infect Dis 1992;165(Suppl 1):S137-8","DOI":"10.1093\/infdis\/165-Supplement_1-S137"},{"key":"10.1016\/j.jaad.2003.12.003_BIB207","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJM199011153232006","article-title":"Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group","volume":"323","author":"Ward","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB208","doi-asserted-by":"crossref","first-page":"S278","DOI":"10.1086\/322563","article-title":"Assessing efficacy of Haemophilus influenzae type b combination vaccines","volume":"33","author":"Granoff","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB209","first-page":"832","article-title":"Haemophilus influenzae type b vaccine","volume":"36","year":"1988","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB210","first-page":"925","article-title":"Food and Drug Administration approval of use of a Haemophilus b conjugate vaccine for infants","volume":"39","year":"1990","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB211","first-page":"1","article-title":"Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older","volume":"40","year":"1991","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2003.12.003_BIB212","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1093\/infdis\/165-Supplement_1-S139","article-title":"Safety, immunogenicity, and efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b vaccine in a United States population","volume":"165","author":"Black","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB213","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00006454-199102000-00004","article-title":"Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b vaccine in a United States population of 61,080 children","volume":"10","author":"Black","year":"1991","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jaad.2003.12.003_BIB214","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJM199106203242503","article-title":"The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex","volume":"324","author":"Santosham","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB215","series-title":"Development and clinical uses of Haemophilus b conjugate vaccine","first-page":"291","article-title":"Lessons from the evaluation of immunogenicity","author":"Daum","year":"1994"},{"key":"10.1016\/j.jaad.2003.12.003_BIB216","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0022-3476(05)80424-X","article-title":"Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines","volume":"120","author":"Decker","year":"1992","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaad.2003.12.003_BIB217","first-page":"296","article-title":"FDA approval of use of a new Haemophilus b conjugate vaccine and a combined diphtheria-tetanus-pertussis and Haemophilus b conjugate vaccine for infants and children","volume":"42","year":"1993","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB218","first-page":"832","article-title":"Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine in infants","volume":"147","author":"Holmes","year":"1993","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.jaad.2003.12.003_BIB219","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0022-3476(05)81786-X","article-title":"Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine","volume":"121","author":"Fritzell","year":"1992","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaad.2003.12.003_BIB220","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1542\/peds.92.6.827","article-title":"Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants","volume":"92","author":"Paradiso","year":"1993","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2003.12.003_BIB221","first-page":"180","article-title":"Immunogenicity and safety of Haemophilus influenzae type b conjugate vaccine (HibTiter) and a combination vaccine of diphtheria, tetanus, pertussis and HibTITER (Tetramune) in two-month-old infants","volume":"31","author":"Huang","year":"1998","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jaad.2003.12.003_BIB222","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1001\/jama.1993.03500020055031","article-title":"Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era","volume":"269","author":"Adams","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB223","series-title":"Vaccines","first-page":"183","article-title":"Haemophilus influenzae vaccines","author":"Ward","year":"1999"},{"key":"10.1016\/j.jaad.2003.12.003_BIB224","first-page":"993","article-title":"Progress toward elimination of Haemophilus influenzae type b disease among infants and children","volume":"47","year":"1998","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB225","first-page":"234","article-title":"Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children","volume":"51","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB226","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(96)06392-1","article-title":"Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster","volume":"349","author":"Booy","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2003.12.003_BIB227","doi-asserted-by":"crossref","first-page":"S198","DOI":"10.1097\/00006454-199809001-00025","article-title":"A nationwide prospective surveillance study in Israel to document pediatric invasive infections, with an emphasis on Haemophilus influenzae type b infections. Israeli Pediatric Bacteremia and Meningitis Group","volume":"17","author":"Dagan","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jaad.2003.12.003_BIB228","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1084\/jem.129.6.1367","article-title":"Human immunity to the meningococcus IV. Immunogenicity of group A and group C meningococcal polysaccharides","volume":"129","author":"Gotschlich","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB229","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM197002192820803","article-title":"Prevention of meningococcal disease by group C polysaccharide vaccine","volume":"282","author":"Artenstein","year":"1970","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB230","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1016\/S0021-9258(18)62260-4","article-title":"Studies on the meningococcal polysaccharides. I. Composition and chemical properties of the group A polysaccharide","volume":"246","author":"Liu","year":"1971","journal-title":"J Biol Chem"},{"issue":"suppl","key":"10.1016\/j.jaad.2003.12.003_BIB231","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1093\/infdis\/136.Supplement.S43","article-title":"Polysaccharide vaccines of group A Neisseria meningitidis and Haemophilus influenzae type b","volume":"136","author":"Makela","year":"1977","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB232","first-page":"667","article-title":"A controlled field trial of a serogroup A meningococcal polysaccharide vaccine","volume":"48","author":"Wahdan","year":"1973","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jaad.2003.12.003_BIB233","first-page":"645","article-title":"A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria","volume":"55","author":"Wahdan","year":"1977","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jaad.2003.12.003_BIB234","first-page":"497","article-title":"Trial of a serogroup A meningococcus polysaccharide vaccine in Nigeria","volume":"5","author":"Sanborn","year":"1972","journal-title":"Prog Immunobiol Stand"},{"key":"10.1016\/j.jaad.2003.12.003_BIB235","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1172\/JCI108235","article-title":"Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants","volume":"56","author":"Gold","year":"1975","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2003.12.003_BIB236","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/infdis\/138.6.731","article-title":"Antibody responses of human infants to three doses of group A Neisseria meningitidis polysaccharide vaccine administered at two, four, and six months of age","volume":"138","author":"Gold","year":"1978","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB237","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0140-6736(85)90224-7","article-title":"Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine","volume":"2","author":"Reingold","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2003.12.003_BIB238","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00006454-200002000-00013","article-title":"Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger","volume":"19","author":"Campagne","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jaad.2003.12.003_BIB239","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1542\/peds.60.5.673","article-title":"Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines","volume":"60","author":"Lepow","year":"1977","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2003.12.003_BIB240","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1086\/515346","article-title":"Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination","volume":"178","author":"Granoff","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB241","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/jama.280.19.1685","article-title":"Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers","volume":"280","author":"MacDonald","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB242","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(02)08416-7","article-title":"Development of vaccines against meningococcal disease","volume":"359","author":"Jodar","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2003.12.003_BIB243","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0140-6736(00)03594-7","article-title":"Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England","volume":"357","author":"Ramsay","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2003.12.003_BIB244","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1073\/pnas.94.1.271","article-title":"Capsule switching of Neisseria meningitidis","volume":"94","author":"Swartley","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB245","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(99)00252-4","article-title":"Meningococcal conjugate vaccines","volume":"354","author":"Maiden","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2003.12.003_BIB246","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1056\/NEJM200001203420319","article-title":"Rapid serogroup switching in Neisseria meningitidis","volume":"342","author":"Vogel","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB247","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1128\/iai.62.8.3391-3395.1994","article-title":"Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults","volume":"62","author":"Anderson","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2003.12.003_BIB248","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1001\/jama.1996.03530430043037","article-title":"Safety and immunogenicity of a serogroup A\/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children","volume":"275","author":"Lieberman","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB249","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/infdis\/174.6.1360","article-title":"Conjugate meningococcal serogroup A and C vaccine","volume":"174","author":"Fairley","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB250","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1001\/jama.279.6.435","article-title":"Efficacy of meningococcal vaccine and barriers to vaccination","volume":"279","author":"Rosenstein","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB251","doi-asserted-by":"crossref","unstructured":"Meningococcal disease prevention and control strategies for practice-based physicians (addendum: recommendations for college students). Committee on Infectious Diseases. Pediatrics 2000;106:1500-4","DOI":"10.1542\/peds.106.6.1500"},{"key":"10.1016\/j.jaad.2003.12.003_BIB252","first-page":"13","article-title":"Prevention and control of meningococcal disease and meningococcal diseases and college students","volume":"49","year":"2000","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB253","unstructured":"Pediatrics AAo. Meningococcal infections. In: Pickering L, editor. Red book. Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village (IL): American Academy of Pediatrics; 2000"},{"key":"10.1016\/j.jaad.2003.12.003_BIB254","unstructured":"The Jordan report: accelerated development of vaccines. Bethesda (MD): National Institute of Allergy and Infectious Diseases, 1998"},{"key":"10.1016\/j.jaad.2003.12.003_BIB255","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1086\/314895","article-title":"A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with Rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers","volume":"180","author":"Evans","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB256","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0140-6736(03)12669-4","article-title":"HIV vaccine fails in phase 3 trial","volume":"361","author":"McCarthy","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2003.12.003_BIB257","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/S0140-6736(98)06493-9","article-title":"Therapeutic immunisation with recombinant gp160 in HIV-1 infection","volume":"353","author":"Sandst\u00f6m","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2003.12.003_BIB258","unstructured":"Birx DL, Davis C, Ruiz N, et al. Results of a phase II double-blind multicenter, placebo controlled HIV therapeutic vaccine trial [abstract]. International Conference on AIDS. Vancouver, July 1996. Abstract 175"},{"key":"10.1016\/j.jaad.2003.12.003_BIB259","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1089\/aid.1998.14.483","article-title":"Immunization of patients with HIV infection","volume":"14","author":"Tsoukas","year":"1998","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.jaad.2003.12.003_BIB260","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/infdis\/167.3.533","article-title":"Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-na\u00efve adults","volume":"167","author":"Graham","year":"1993","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB261","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0891-5520(05)70045-3","article-title":"HIV vaccines","volume":"13","author":"Frey","year":"1999","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jaad.2003.12.003_BIB262","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/jcp.51.10.725","article-title":"AIDS vaccine development","volume":"51","author":"Oxford","year":"1998","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB263","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1086\/515288","article-title":"Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group","volume":"177","author":"Clements-Mann","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB264","unstructured":"Belshe RB, Stevens C, Gorse G, et al. Phase II evaluation of a live recombinant canarypox (AVLAC) vector HIV-1 vaccine with or without gp120 subunit HIV-1 vaccine [abstract]. International Society for Sexually Transmitted Diseases Research; July 11-14, 1999; Denver, CO. Abstract 227"},{"key":"10.1016\/j.jaad.2003.12.003_BIB265","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1073\/pnas.94.4.1396","article-title":"Clad B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers","volume":"94","author":"Ferrari","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB266","unstructured":"Evans T, Corey L, Clements-Mann ML, et al. CD8+CTL induced in AIDS Vaccine Evaluation Group phase I trials using canarypox vectors (ALVAC) encoding multiple HIV gene products (vCP125, vCP205, vCP300) given with or without subunit boost. Paper presented at: World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland"},{"key":"10.1016\/j.jaad.2003.12.003_BIB267","unstructured":"Doepel LK. NIAID opens first AIDS vaccine trial in Africa. NIAID News. National Institute of Allergy and Infectious Diseases, February 8, 1999"},{"key":"10.1016\/j.jaad.2003.12.003_BIB268","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0092-8674(01)00482-2","article-title":"An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants","volume":"106","author":"Rose","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.jaad.2003.12.003_BIB269","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1001\/jama.288.21.2671","article-title":"In HIV vaccine efforts, new strategies and patience are needed in equal measure","volume":"288","author":"Stephenson","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB270","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nm0597-526","article-title":"Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination","volume":"3","author":"Boyer","year":"1997","journal-title":"Nature Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB271","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/jid.1938.26","article-title":"Formulized herpes virus therapy and neutralizing substance in herpes simplex","volume":"1","author":"Frank","year":"1938","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB272","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1086\/514103","article-title":"Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B","volume":"176","author":"Straus","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB273","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.282.4.331","article-title":"Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection","volume":"282","author":"Corey","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB274","unstructured":"Leroux-Roels G, Moreau E, Desombere I, et al. Safety, humoral and cellular immune responses of three different doses of glycoprotein D(gD2t) in herpes simplex vaccine with aluminum and MPL. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997; New Orleans"},{"key":"10.1016\/j.jaad.2003.12.003_BIB275","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMoa011915","article-title":"GlaxoSmithKline Herpes Vaccine Efficacy Study Group. Glycoprotein-D-adjuvant vaccine to prevent genital herpes","volume":"347","author":"Stanberry","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB276","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/infdis\/175.1.16","article-title":"A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease","volume":"175","author":"Boursnell","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB277","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/0264-410X(95)00259-4","article-title":"Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine","volume":"14","author":"McLean","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2003.12.003_BIB278","doi-asserted-by":"crossref","first-page":"11414","DOI":"10.1073\/pnas.93.21.11414","article-title":"Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease","volume":"93","author":"McClements","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB279","first-page":"69","article-title":"DNA vaccines and immunity to herpes simplex virus","volume":"226","author":"Rouse","year":"1998","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB280","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/infdis\/158.3.602","article-title":"In vivo behavior of genetically engineered herpes simplex viruses R7017 and R 7020","volume":"58","author":"Meignier","year":"1988","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB281","unstructured":"Cadoz M, Micoud M, Seigneurin JM. Phase I trial of R7020: a live-attenuated recombinant herpes simplex virus (HSV) candidate vaccine. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992; Anaheim [CA]"},{"key":"10.1016\/j.jaad.2003.12.003_BIB282","unstructured":"Reichman R, Balsley J, Carlin D, et al. Evaluation of the safety and immunogenicity of a recombinant HPV-11 L1 virus like particle vaccine in healthy adult volunteers. Paper presented at: International Papillomavirus Conference; January 9-15, 1999; Charleston [SC]"},{"key":"10.1016\/j.jaad.2003.12.003_BIB283","unstructured":"Zhang LF, Zhou J, Shao C, et al. A phase 1 trial of HPV 6 B virus like particles as immunotherapy for genital warts. Paper presented at: International Papillomavirus Conference; January 9-15, 1999; Charleston [SC]"},{"key":"10.1016\/j.jaad.2003.12.003_BIB284","unstructured":"Silva DD, Nieland J, Greenstone H, Schiller J, Kast W. Chimeric papillomavirus virus-like particles induce antigen-specific therapeutic immunity against tumours expressing the HPV-16 E7 protein. Paper presented at: International Papillomavirus Conference; January 9-15, 1999; Charleston [SC]"},{"key":"10.1016\/j.jaad.2003.12.003_BIB285","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB286","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0140-6736(96)90674-1","article-title":"A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer","volume":"347","author":"Borysiewicz","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2003.12.003_BIB287","unstructured":"Lacey CJ, Monteiro EF, Thompson HS, et al. A phase IIa study of a therapeutic vaccine for genital warts. Paper presented at: Medical Society for the Study of Venereal Disease; July 1997; Oxford, England"},{"key":"10.1016\/j.jaad.2003.12.003_BIB288","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2741\/A356","article-title":"Papillomavirus vaccines","volume":"3","author":"Duggan-Keen","year":"1998","journal-title":"Front Biosci"},{"key":"10.1016\/j.jaad.2003.12.003_BIB289","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1128\/iai.65.8.3328-3336.1997","article-title":"Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice","volume":"65","author":"Nardelli-Haefliger","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2003.12.003_BIB290","doi-asserted-by":"crossref","first-page":"8467","DOI":"10.1128\/jvi.71.11.8467-8474.1997","article-title":"Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA","volume":"71","author":"Jensen","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB291","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s002620050302","article-title":"Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains","volume":"43","author":"Krul","year":"1996","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jaad.2003.12.003_BIB292","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00002371-199508000-00002","article-title":"Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor","volume":"18","author":"Ossevoort","year":"1995","journal-title":"J Immunother"},{"key":"10.1016\/j.jaad.2003.12.003_BIB293","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3201\/eid0901.020168","article-title":"Cost effectiveness of a potential vaccine for human papillomavirus","volume":"9","author":"Sanders","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB294","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/br.31.1.35-53.1967","article-title":"Experimentally induced immunity in the mycoses","volume":"31","author":"Kong","year":"1967","journal-title":"Bacteriol Rev"},{"key":"10.1016\/j.jaad.2003.12.003_BIB295","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s100960000395","article-title":"The exciting new future of antifungal therapy","volume":"19","author":"Neely","year":"2000","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2003.12.003_BIB296","first-page":"95","article-title":"Antibody and\/or cell-mediated immunity, protective mechanisms in fungal disease","volume":"36","author":"Casadevall","year":"1998","journal-title":"Med Mycol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB297","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1128\/CMR.10.4.585","article-title":"Prospects for the development of fungal vaccines","volume":"10","author":"Deepe","year":"1997","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jaad.2003.12.003_BIB298","doi-asserted-by":"crossref","unstructured":"Bistoni F, Vecchiarelli A, Cenci E, Puccetti P, Marconi P, Cassone A. Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect Immun 1986;51:668-74","DOI":"10.1128\/iai.51.2.668-674.1986"},{"key":"10.1016\/j.jaad.2003.12.003_BIB299","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1128\/iai.63.7.2619-2624.1995","article-title":"Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection","volume":"63","author":"Cassone","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2003.12.003_BIB300","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0923-2494(98)80760-8","article-title":"Protective immunity in experimental Candida vaginitis","volume":"149","author":"Fidel","year":"1998","journal-title":"Res Immunol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB301","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1128\/iai.65.8.3399-3405.1997","article-title":"Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats","volume":"65","author":"Bernardis","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2003.12.003_BIB302","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1128\/IAI.66.12.5771-5776.1998","article-title":"A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection","volume":"66","author":"Han","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2003.12.003_BIB303","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.1128\/iai.62.12.5353-5360.1994","article-title":"A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice","volume":"62","author":"Mencacci","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2003.12.003_BIB304","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1128\/AAC.44.10.2653-2658.2000","article-title":"CD4-T-cell-mediated resistance to systemic candidiasis induced by a membrane fraction of Candida albicans","volume":"44","author":"Mizutani","year":"2000","journal-title":"Antimicrob Ag Chemother"},{"key":"10.1016\/j.jaad.2003.12.003_BIB305","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/IAI.67.2.826-833.1999","article-title":"Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis","volume":"67","author":"Cardenas-Freytag","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2003.12.003_BIB306","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1128\/iai.63.7.2714-2719.1995","article-title":"Antibody response that protects against disseminated candidiasis","volume":"63","author":"Han","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2003.12.003_BIB307","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1086\/314779","article-title":"Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis","volume":"179","author":"Han","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2003.12.003_BIB308","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/0264-410X(95)00256-Z","article-title":"Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model","volume":"14","author":"Devi","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2003.12.003_BIB309","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1128\/AAC.38.3.580","article-title":"Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B","volume":"38","author":"Mukherjee","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jaad.2003.12.003_BIB310","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1128\/CMR.13.1.122","article-title":"Potential role of phospholipases in virulence and fungal pathogenesis","volume":"13","author":"Ghannoum","year":"2000","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jaad.2003.12.003_BIB311","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1439-0507.1995.tb00404.x","article-title":"New systematically active antimycotics from the beta-blocker category","volume":"38","author":"Hanel","year":"1995","journal-title":"Mycoses"},{"key":"10.1016\/j.jaad.2003.12.003_BIB312","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4269\/ajtmh.1995.52.287","article-title":"Control of zoonotic visceral leishmaniasis","volume":"52","author":"Tesh","year":"1995","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jaad.2003.12.003_BIB313","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4269\/ajtmh.1996.55.125","article-title":"The logic of visceral leishmaniasis control","volume":"55","author":"Dye","year":"1996","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jaad.2003.12.003_BIB314","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/CMR.14.2.229-243.2001","article-title":"Leishmaniasis","volume":"14","author":"Handman","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jaad.2003.12.003_BIB315","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1046\/j.1365-3156.2002.00911.x","article-title":"Molecular biological applications in the diagnosis and control of leishmaniasis and parasite identification","volume":"7","author":"Schallig","year":"2002","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.jaad.2003.12.003_BIB316","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0952-7915(96)80042-2","article-title":"DNA vaccines","volume":"8","author":"Ulmer","year":"1996","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB317","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/1380-2933(96)00043-7","article-title":"Gene vaccines","volume":"2","author":"Wahren","year":"1996","journal-title":"Immunotechnology"},{"key":"10.1016\/j.jaad.2003.12.003_BIB318","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-1759(99)00104-0","article-title":"Nucleic acid immunization","volume":"229","author":"Hassan","year":"1999","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jaad.2003.12.003_BIB319","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1089\/hum.1998.9.13-1899","article-title":"Genetic immunization with glycoprotein 63 cDNA results in a T helper cell type 1 response and protection in a murine model of leishmaniasis","volume":"9","author":"Walker","year":"1998","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jaad.2003.12.003_BIB320","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1084\/jem.186.7.1137","article-title":"Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major","volume":"186","author":"Gurunathan","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB321","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1128\/IAI.69.8.4719-4725.2001","article-title":"Leishmania donovani p36 (LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis","volume":"69","author":"Melby","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2003.12.003_BIB322","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0952-7915(00)00118-7","article-title":"DNA vaccines","volume":"12","author":"Gurunathan","year":"2000","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB323","first-page":"45","article-title":"DNA vaccines","volume":"104","author":"Klinman","year":"2000","journal-title":"Dev Biol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB324","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1385\/MB:19:3:245","article-title":"Plasmid DNA vaccines. Immunology, tolerance and autoimmunity","volume":"19","author":"Mor","year":"2001","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.jaad.2003.12.003_BIB325","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0169-4758(99)01455-6","article-title":"The Leishmania genome comes of age","volume":"15","author":"Ivens","year":"1999","journal-title":"Parasitol Today"},{"key":"10.1016\/j.jaad.2003.12.003_BIB326","first-page":"641","article-title":"Current perspectives on the use of intravenous immunoglobulin","volume":"41","author":"Dickler","year":"1996","journal-title":"Adv Intern Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB327","first-page":"518","article-title":"Renal insufficiency and failure associated with immune globulin intravenous therapy","volume":"48","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB328","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1128\/CMR.5.2.146","article-title":"Antiviral therapy","volume":"5","author":"Bean","year":"1992","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jaad.2003.12.003_BIB329","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/00006454-198509000-00005","article-title":"Bacterial infections in the acquired immunodeficiency syndrome of children","volume":"4","author":"Bernstein","year":"1985","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jaad.2003.12.003_BIB330","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1097\/00006454-198605010-00014","article-title":"Intravenous gamma-globulin in infant acquired immunodeficiency syndrome","volume":"5","author":"Calvelli","year":"1986","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jaad.2003.12.003_BIB331","first-page":"143","article-title":"Restoration of suppressor T-cell functions in children with AIDS following intravenous gamma globulin treatment","volume":"140","author":"Gupta","year":"1986","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.jaad.2003.12.003_BIB332","first-page":"162","article-title":"Treatment of immunodeficiency virus antibody positive children with intravenous immunoglobulin","volume":"52","author":"Oleski","year":"1987","journal-title":"Vox Sang"},{"key":"10.1016\/j.jaad.2003.12.003_BIB333","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJM199411033311802","article-title":"Controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection","volume":"331","author":"Spector","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB334","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.1983.03330250028023","article-title":"Effect of immunoglobulin on hepatitis A in day-care centers","volume":"249","author":"Hadler","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB335","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jama.1960.03030070001001","article-title":"Infectious hepatitis. Studies on the effect of gamma globulin and on the incidence of inapparent infection","volume":"174","author":"Krugman","year":"1960","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB336","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jama.1969.03160200017004","article-title":"Hepatitis prophylaxis abroad","volume":"209","author":"Woodson","year":"1976","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB337","first-page":"2387","article-title":"Immunoprophylaxis of hepatitis B viral reinfection in recipients of human liver allografts","volume":"19","author":"Lauchart","year":"1987","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jaad.2003.12.003_BIB338","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0140-6736(91)92515-4","article-title":"Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients","volume":"337","author":"Samuel","year":"1991","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2003.12.003_BIB339","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2893.1997.tb00171.x","article-title":"Hepatitis B virus and liver transplantation","volume":"4","author":"Grellier","year":"1997","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jaad.2003.12.003_BIB340","first-page":"1","article-title":"Prevention of varicella","volume":"45","year":"1996","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2003.12.003_BIB341","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJM198602273140907","article-title":"Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA","volume":"314","author":"Burks","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB342","unstructured":"IVIG transmission of hepatitis C. FDA Med Bull 1994;24:3-4"},{"key":"10.1016\/j.jaad.2003.12.003_BIB343","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1001\/jama.288.24.3155","article-title":"Current controversies in vaccination","volume":"288","author":"Maldonado","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB344","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/S0140-6736(96)07495-8","article-title":"Global mortality, disability, and the contribution of risk factors","volume":"349","author":"Murray","year":"1997","journal-title":"Lancet"},{"year":"2001","series-title":"National vital statistics system for numbers of death","key":"10.1016\/j.jaad.2003.12.003_BIB345"},{"key":"10.1016\/j.jaad.2003.12.003_BIB346","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/adc.87.1.22","article-title":"Antivaccination activists on the world wide web","volume":"87","author":"Davies","year":"2002","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaad.2003.12.003_BIB347","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1001\/jama.287.24.3245","article-title":"Content and design attributes of antivaccination web sites","volume":"287","author":"Wolfe","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB348","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jama.1994.03510290057037","article-title":"Cost-effectiveness of a routine varicella vaccination program for US children","volume":"271","author":"Lieu","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB349","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJM200102223440804","article-title":"Intussusception among infants given an oral rotavirus vaccine","volume":"344","author":"Murphy","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB350","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/jama.285.9.1183","article-title":"Time trends in autism and in MMR immunization coverage in California","volume":"285","author":"Dales","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2003.12.003_BIB351","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/bmj.322.7284.460","article-title":"Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners","volume":"322","author":"Kaye","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2003.12.003_BIB352","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa021134","article-title":"A population-based study of measles, mumps, and rubella vaccination and autism","volume":"347","author":"Madsen","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB353","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJM200102013440502","article-title":"Hepatitis B vaccination and the risk of multi-ple sclerosis","volume":"344","author":"Ascherio","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB354","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM200102013440501","article-title":"Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group","volume":"344","author":"Confavreux","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB355","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/bmj.318.7192.1169","article-title":"Association between type 1 diabetes and Haemophilus influenzae type b vaccination","volume":"318","author":"Karvonen","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2003.12.003_BIB356","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.2337\/diacare.22.10.1694","article-title":"Lack of association between early childhood immunizations and beta-cell autoimmunity","volume":"22","author":"Graves","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaad.2003.12.003_BIB357","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm0598-607","article-title":"Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato","volume":"4","author":"Tacket","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2003.12.003_BIB358","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nm0598-550","article-title":"Plants are not just passive creatures!","volume":"4","author":"Arakawa","year":"1998","journal-title":"Nat Med"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962203045237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962203045237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T21:29:32Z","timestamp":1759267772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962203045237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":358,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S0190962203045237"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2003.12.003","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2004,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccines and immunotherapies for the prevention of infectious diseases having cutaneous manifestations","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2003.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2003.12.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}